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Bacterial infections including Mycoplasma pneumoniae (Mp) are a major cause of exacerba-
tions in chronic obstructive pulmonary disease (COPD). Cigarette smoke (CS) is the leading
cause of COPD, and affects the function of alveolar macrophages that act as the first line of
defense against the invading respiratory pathogens. Macrophages express a transmembrane re-
ceptor called macrophage receptor with collagenous structure (MARCO) that is involved in the
clearance of microorganisms. Whether CS down-regulates MARCO and eventually decreases the
clearance of Mp has not been investigated. We utilized human monocytic cell line (THP-1)-
derived macrophages to examine the effects of CS extract (CSE) on MARCO expression and
Mp growth. Specifically, macrophages were pre-exposed to CSE for 6 h, and then infected with
or without Mp for 2 h. MARCO was examined at both mRNA and protein levels by using real-time
PCR and immunofluorescent staining, respectively. Mp in the supernatants was quantified by
quantitative culture. In addition, a neutralizing MARCO antibody was added to macrophages
to test if blockade of MARCO impaired Mp clearance. We found that CSE significantly decreased
MARCO expression in a dose-dependant manner at 6 h post-CSE. Mp levels in CSE-treated cells
were higher than those in non-CSE-treated cells, indicating a decreased pathogen clearance.
Additionally, neutralizing MARCO in macrophages markedly increased Mp levels. Our results in-
dicate that cigarette smoke exposure down-regulates MARCO expression in macrophages,
which may be in part responsible for impaired bacterial (e.g., Mp) clearance.
ª 2008 Elsevier Ltd. All rights reserved.Medical and Research Institute (FAMRI).
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Cigarette smoke and mycoplasma clearance 1605Introduction with the use of a peristaltic pump into 25 ml of sterile RPMI-Table 1 Time course study of MARCO mRNA expression in
THP-1 cell-derived macrophages (nZ 3)
Time points
(h)
MARCO mRNA relative
level e control
(no CSE)
MARCO mRNA relative
level e 20% CSE
2 1.8 1.2 1.5 2.8
6 3.0 1.5 1.0 2.3
24 5.9 1.5 6.1 2.3
48 5.6 1.5 5.8 1.8Bacterial infections continue to pose a huge burden on COPD
patients. Many species of bacteria including nontypeable
Haemophilus influenzae, Moraxella catarrhalis, Streptococ-
cus pneumoniae and Chlamydia pneumoniae have been
detected in COPD lungs.1 In addition, Mycoplasma pneumo-
niae (Mp) was found to be one of the common (14%) patho-
gens in COPD patients.2,3 One of the fundamental research
questions is: why are COPD patients more susceptible to
bacterial infections than normal human subjects? In other
words, is there any deficiency of host innate immune
responses to an invading pathogen in COPD patients?
Cigarette smoke (CS), a leading cause of COPD, may
predispose COPD patients to bacterial infections, and
exaggerate inflammatory responses by various mechanisms.
Mucosal hypertrophy, increased mucus production,
decreased tracheal mucosal velocity, increased lung neutro-
phils and production of IL-8 (a chemoattractant for neutro-
phils), and increased expression of adhesion molecules like
E-selectin are some of the effects that CS exerts in COPD
patients with bacterial infections.4e10 Further exploration
into the relationship between CS and COPD reveals that CS
is also involved in the activation of alveolar macrophages
that contribute to the pathogenesis of COPD by releasing var-
ious inflammatory mediators such as LTB4, PGE2, IL-8, TNF-a,
TGF-b, superoxide anions, iNOS and proteases.11e18
The macrophages utilize several mechanisms contribut-
ing to bacterial clearance. These include superoxide an-
ions, nitric oxide and cell receptor (e.g., Toll-like
receptors)-mediated production of inflammatory cytokines
involved in the recruitment of inflammatory cells (e.g.,
neutrophils). The role of cell surface receptors in macro-
phage host defense functions has been under intensive
investigation. Macrophages have a very active plasma
membrane expressing high densities of different types of
receptors like immumoglobulin receptors, complement
receptors, mannose receptors and TLRs. Among them,
scavenger receptors (SRs) have been proposed to be critical
in normal lung defense. SRs are transmembrane proteins on
the surface of macrophages and exhibit high-affinity bind-
ing to various ligands. These receptors are divided into
classes A, B and C based on their structure.19,20 Recently
included within class A of SRs is a novel receptor, macro-
phage receptor with collagenous structure (MARCO).
MARCO was initially discovered in mice using a human
type 3-collagen cDNA probe, and was later identified as a re-
ceptor binding to bacteria.21e23
In the current study, we proposed that MARCO is
involved in the clearance of Mp. We further hypothesized
that CS would inhibit MARCO expression, thus impairing
bacterial clearance. To test our hypothesis, we used
a human macrophage cell culture system to examine the
interplay between CS exposure, MARCO and Mp.
Materials and methods
Cigarette smoke extract (CSE) preparation
The CSE was prepared as previously described.24 Briefly, one
83 mmunfiltered research grade 2R1 cigarettewas combusted1640 medium that did not contain any serum (e.g., fetal bo-
vine serum). The smoke-saturated RPMI-1640 medium was fil-
ter-sterilized through a 0.22-mm filter, and the resulting
preparationwas considered as 100%CSEwhichwas usedwithin
30 min of preparation by diluting it into macrophage culture
medium to perform the cell culture experiments.
Mycoplasma pneumoniae (Mp) preparation
Mp (strain FH; ATCC 15531) was grown in SP-4 broth for 5
days at 37 C in T-75 flasks, scraped off the flasks, and was
then passed through a 26-gauge needle to prevent Mp self-
aggregation. Mp was then plated on PPLO plates to quantify
colony forming unit (CFU). The remainder of Mp at passage
4 was frozen at 80 C, and subsequently used for cell
culture experiments. On the infection day, frozen Mp ali-
quots were thawed, spun, resuspended in SP-4 broth, and
incubated for 2 h at 37 C. Mp was then spun at 6000 rpm
for 5 min and resuspended in cell culture media to yield
the indicated concentrations for infecting cells.25
Cell culture
The human monocytic cell line THP-1 cells were obtained
from the American Type Culture Collection (ATCC, product
number TIB-202), and the cells in RPMI-1640 medium with
10% fetal bovine serum (FBS, GIBCO, Invitrogen) were plated
on 12-well plates with 4 105 cells/well. To these cells
100 nM phorbol 12-myristate 13-acetate (PMA, Sigma-
Aldrich) was added overnight (16 h) to induce THP-1 cell
differentiation into macrophages. The next day, PMA along
with non-adherent cells, was washed off three times with
PBS, resulting in adherent macrophages on the plates.
Preliminary experiments (nZ 3) were performed to
optimize the impact of duration of CSE exposure on MARCO
expression. THP-1 cell-derived macrophages were exposed
to various concentrations of CSE (5, 10 and 20%) for 2, 6,
24 and 48 h. Cells were collected for measuring MARCO
mRNA expression by real-time PCR. The time point, which
yielded the most significant and consistent reduction in
MARCO expression, was seen at 6 h (about 3-fold decrease
with 20% CSE, Table 1). At 2, 24 and 48 h, there was no
significant change in MARCO expression with all the three
concentrations of CSE used. Therefore, CSE exposure for
6 h was chosen as the optimal condition for all the experi-
ments described in Results section.
To validate the use of 20% CSE in our cell culture
experiments, nicotine content in 20% CSE preparation was
1606 M. Baqir et al.measured at 3.4 0.05 mg/ml by using the HPLC method,
which is relevant to the physiologic levels of nicotine in
human smokers’ lungs based on the following facts: (1)
82e92% of nicotine in lung epithelial lining fluid (ELF)
diffuses into the blood stream26; (2) The volume of ELF in
human smokers is 2.4 1.4 ml,27 which is about 1000-fold
lower than that of serum (averageZ 2750 ml for an adult);
and (3) Blood nicotine concentration in human smokers is
6e52 mg/L (or 0.006e0.052 mg/ml).26 Therefore, to reach
a similar concentration of nicotine between ELF and serum,
the initial concentration of nicotine in ELF is most likely 100
to 1000-fold higher than that is finally seen in the serum.
Mp culture in THP-1 cell-derived macrophages
THP-1 cell-derived macrophages were pre-treated with CSE
or PBS for 6 h, and then infected with Mp (1 CFU/cell) for
2 h. Immediately after the addition of Mp into THP-1 cell-
derived macrophages, the 12-well cell culture plates were
gently (200 rpm, 30 s) agitated on a plate shaker to allow
Mp to attach to the cells through diffusion. Cell superna-
tants were collected and serially (10-fold) diluted in SP4
broth with 10 ml of this broth being plated onto PPLO agar
plates (Remel, KS, USA). After 7 days of incubation at
37 C, 5% CO2, CFU on the PPLO plates was counted under
the microscope.
It wasworth noting that we chose 2 h of Mp infection since
ourpreliminaryexperiments (nZ 3)demonstratedamaximal
delay of Mp clearance in THP-1 cell-derived macrophages
that were pre-treated with 20% CSE and infected with Mp
at 1 CFU/cell. At other time points (4 and 24 h) and doses
(5 and 10 CFU/cell) of Mp infection, there was a minimal
effect of CSE treatment on Mp clearance. Also, to exclude
the possibility of direct killing effects of CSE on Mp, macro-
phage-free Mp was incubated with or without 20% CSE for
6 h (nZ 6), followed by culture on PPLO plates. It was found
that CFU counts with or without CSE treatment were similar
(71 8.6 104 vs. 65 6.7 104 CFU/ml, p> 0.05). Thus,
20% CSE alone does not appear to exert any bactericidal
activity against Mp. To address whether CSE may affect
Mp’s ability to bind the macrophages, we performed a CSE
washout experiment. After 6 h of incubation, CSE was either
rinsed from macrophages or stayed with the cells, and then
infected with Mp for 2 h. Our data suggest that Mp levels
were similar between macrophages with and without
washout of CSE, suggesting that the increased levels of Mp
in CSE-pretreated cells may not be caused by CSE-induced
impairment of Mp binding to macrophages.
MARCO antibody treatment
Mouse anti-humanMARCO antibody (Clone PLK1,mouse IgG3)
was obtained from Hycult Biotechnology (The Netherlands).
This antibody was used to inhibit MARCO function in THP-1
cell-derived macrophages, and also to detect MARCO protein
expression using immunofluorescent staining. In MARCO
blocking experiments, anti-MARCO antibody (0.002e0.2 mg/
ml) or matched mouse IgG3 isotype control was added to
THP-1 cell-derived macrophages 1 h prior to Mp infection
(1 CFU/cell). After 2 h of Mp infection, supernatants were
collected to perform quantitative mycoplasma culture.Real-time RT-PCR
Total RNA was extracted from THP-1 cell-derived macro-
phages and treatedwith DNase 1 (Ambion, Austin, TX, USA) to
remove any contaminating genomic DNA. Reverse transcrip-
tion (RT) was performed using 1 mg of total RNA and random
hexamers in a 50 ml reaction according to the manufacturer’s
protocol (Applied Biosystems, Foster City, CA, USA). The
human MARCO primers and probe as shown below were
designed using the Primer Express software (Applied Biosys-
tems). Forward primer: 50-CTGGTGGTCCAAGTTCTGAATCT-
30; reverse primer: 50-TCAGCCGCCAGAGTGTCA-30; and probe:
50-CTCCGGGTCCTGGAGATGTATTTCCTCA-30. Real-time PCR
was performed on the ABI Prism 7700 sequence detector
(Applied Biosystems). The 25 ml PCR contained 30 ng of
cDNA, 100 nM fluogenic probe, and 100 nM primers and other
components from the TaqMan RT-PCR kit (Applied Biosys-
tems). GAPDH mRNA was evaluated as an internal positive
control. The comparative Ct method was used to calculate
the relative mRNA levels of target genes.28
MARCO immunofluorescent staining
Immunofluorescent staining was performed to determine
MARCO protein expression level after CSE exposure. THP-
1 cell-derived macrophages on 8-well chamber slides
were treated with or without CSE (5, 10 and 20%) for
6 h, fixed with methanol, and then incubated with the
MARCO antibody or mouse IgG3 (isotype control), followed
by FITC-conjugated anti-mouse IgG antibody (Vector
Laboratory). Before staining with the relevant antibody,
cells were incubated with excess of horse normal serum
for 30 min to block nonspecific binding. A Scion image
analysis program (National Institutes of Health, Bethesda,
MD) was used to measure the mean fluorescent intensity
that was then normalized to the total number of cells
on the slide.
Statistical analysis
Normally distributed data are presented as mean SEM and
compared using the matched-pairs t-test. Non-normally dis-
tributed data are expressed as medians with interquartile
(25e75%) ranges and compared using the Wilcoxon rank-
sum test. A value of p< 0.05 was considered significant.
Results
CSE decreases MARCO mRNA expression
MARCO mRNA expression levels as measured after 6 h of ex-
posure to varying concentrations of CSE are shown in Fig. 1.
When compared with the control, CSE at 5, 10 and 20%
resulted in a dose-dependent decrease of MARCO mRNA
expression. The % change of MARCO mRNA levels over the
controls was 74 25% (pZ 0.06), 64 18% (pZ 0.01), and
54 29% (pZ 0.03) for 5, 10 and 20% CSE, respectively.
CSE did not affect cell viability as assessed by trypan blue
exclusion assay (cell viability, 20% CSEZ 98.6 0.2%;
control (no CSE)Z 94.7 2.1%, p> 0.05).
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Figure 1 Cigarette smoke extract (CSE) decreases MARCO
mRNA expression in THP-1 cell-derived macrophages. Cells
were with CSE at various concentrations, or with cell culture
medium (control, no CSE) for 6 h. MARCO mRNA expression
was determined using real-time PCR, and expressed as %
change over the controls. Data are expressed as mean SEM
(nZ 5). *p< 0.05 compared to controls (no CSE).
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Figure 2 Cigarette smoke extract (CSE) decreases MARCO
protein expression in THP-1 cell-derived macrophages in
a dose-dependent manner. Cells were with CSE at various con-
centrations, or with cell culture medium (control, no CSE) for
6 h. MARCO protein expression on macrophages was deter-
mined using immunofluorescent staining. (A) Quantitative
data of MARCO immunofluorescent staining are expressed as
mean SEM (nZ 4). *p< 0.05 compared to controls (no CSE
treatment). (B) THP-1 cell-derived macrophages without
MARCO antibody incubation (mouse IgG isotype control) did
not show fluorescent staining. Macrophages without CSE treat-
ment (C) demonstrated stronger MARCO staining than those
with 20% CSE (D) treatment. Original magnifications, x200.
Cigarette smoke and mycoplasma clearance 1607CSE inhibits MARCO protein expression
To confirm if inhibition of MARCO mRNA expression by CSE
was coupled with protein reduction, immunofluorescent
staining was performed to examine MARCO protein.
Fig. 2AeD illustrates the changes and pattern of MARCO im-
munofluorescent staining in THP-1 cell-derived macrophages
that were exposed to varying concentrations of CSE for 6 h.
Measurement of MARCO fluorescent intensity on THP-1
cell-derived macrophages with CSE treatment was normal-
ized to the controls (i.e., no CSE exposure) and hence
expressed as % change over the controls. Similar to MARCO
mRNA data, a dose-dependant decrease in MARCO protein
expression was found in macrophages upon 6 h CSE
exposure. The % change of MARCO protein over the controls
was 99.6 58.3 (pZ 1.0), 83.8 30.8 (pZ 1.0), and
68.1 15.5 (pZ 0.014) for 5, 10 and 20% CSE, respectively.
CSE impairs Mp clearance in macrophages
As shown in Fig. 3, Mp levels in the supernatants of THP-1
cell-derived macrophages with 6 h of 20% CSE pre-treatment
were significantly (pZ 0.008) higher than those without CSE
treatment in all six independent experiments.
MARCO blockade increases Mp levels in the
supernatants of macrophages
Blocking MARCO with a neutralizing antibody (0.002, 0.02,
0.2 mg/ml) (nZ 4) resulted in an increase in Mp counts in
the supernatants of THP-1 cell-derived macrophages
(Fig. 4). MARCO antibody-induced % increase in Mp levels
over the controls was 17.2 3.4 (pZ 0.7), 29.0 3.4
(pZ 0.03), and 29.0 1.7 (pZ 0.004) for MARCO antibody
at 0.002, 0.02 and 0.2 mg/ml, respectively. MARCO
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Figure 3 Pre-treatment of THP-1 cell-derived macrophages
with cigarette smoke extract (CSE) impaired the clearance of
Mycoplasma pneumoniae (Mp). Cells were exposed to cell cul-
ture medium (control) or 20% CSE for 6 h, and then infected
with Mp (1 CFU/cell) for 2 h. Supernatants were collected for
Mp culture. Mp levels in supernatants from CSE pre-treatment
(CSEþMp) cells were significantly higher than those in super-
natants from cell culture medium pre-treated cells (Mp).
Data are expressed as mean SEM (nZ 6).
1608 M. Baqir et al.neutralizing antibody at 0.02 mg/ml reached its plateau in
inhibiting Mp clearance.
To explain the blocking effects of MARCO neutralizing
antibody on Mp clearance, we co-localized MARCO and Mp
on THP-1 cell-derived macrophages. Briefly, macrophages
on 8-well chamber slides were incubated with yellow
fluorescent protein (YFP)-tagged Mp (1 CFU/cell)29 for 2 h,
and then fixed in methanol for double immunofluorescent
staining of MARCO and YFP by using a monoclonal anti-0 0.002 0.02 0.2
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Figure 4 Blocking MARCO with a neutralizing anti-MARCO an-
tibody increased Mycoplasma pneumoniae (Mp) levels in super-
natants of THP-1 cell-derived macrophages. Anti-MARCO
antibody was added to macrophages 1 h prior to Mp (1 CFU/
cell) infection. At 2 h post-Mp, cell supernatants were col-
lected to perform Mp culture. The results were expressed as
mean SEM, nZ 4. *p< 0.05 compared to cells without
MARCO antibody treatment (mouse IgG isotype control).MARCO antibody and a rabbit polyclonal anti-YFP antibody
(Abcam Inc., Cambridge, MA), followed by FITC-conjugated
anti-mouse IgG and Texas Red-conjugated anti-rabbit IgG.
Fig. 5 demonstrates co-localization of MARCO with Mp on
THP-1 cell-derived macrophages.Discussion
In this study we found that CSE down-regulated MARCO
expression in human macrophages at both mRNA and
protein levels. This decreased MARCO expression may be
partially responsible for impaired clearance of Mp in that
a neutralizing antibody against MARCO significantly
impaired Mp clearance. Our data, for the first time, have
provided evidence for a role of MARCO in host defense
against bacterial (i.e., Mp) infection in a cigarette smoke
exposure environment.
How MARCO is engaged in Mp clearance remains un-
certain. It is possible that MARCO may directly bind to Mp,
thus mediating the phagocytic process since the treatment
with the MARCO neutralizing antibody resulted in impaired
Mp clearance in macrophages. Further, MARCO was shown
to be co-localized with Mp in our experiments. Our results
are supported by an early study indicating a direct binding
of MARCO to typical bacteria or their structural components
including LPS.30,31 A previous study also suggests that
MARCO recognizes uteroglobin-related protein 1 (UGRP1),
a secretory protein from airway epithelial cells that can
directly bind to bacteria.32 Thus, in the lungs, UGRP1 could
serve as an additional mechanism to bridge Mp and MARCO
to promote bacterial (e.g., Mp) clearance by macrophages.
It is not clear whether CS may increase the susceptibility
of COPD patients to bacterial infections through inhibiting
surface receptors such as MARCO. In our study, CSEwas found
to down-regulate MARCO expression in a dose-dependant
manner. The down-regulation of MARCO on the surface of
macrophages was accompanied by significant impairment of
Mp clearance after Mp infection. Our findings suggest that CS
may inhibit the ability of innate immune cells (i.e., macro-
phages) to eliminate the invading pathogens, thus leading to
an increased load of bacteria in the lungs of COPD patients.
We realize that there are other scavenger receptors such
as SR-AI/II, scavenger receptor with C-type lectin (SRCL)
and SCARA5 receptor, which may also contribute to non-
opsonised phagocytosis of pathogens (e.g., Mp) by macro-
phages. Indeed, SR-AI/II was shown to mediate phgocytosis
of Streptococcus pneumoniae in mice.33 Additionally, our
current study has not revealed the detailed molecular
mechanisms by which CSE suppresses macrophage MARCO
expression. We propose that CSE may decrease MARCO
expression in macrophages by altering inflammatory cyto-
kines. For example, hydroquinone, a major metabolite of
benzene present in large quantities in cigarette tar, was
shown to inhibit production of IL-12 (a Th1-driving cytokine)
in both primary mouse macrophages and RAW164.7 mono-
cytic cells.34 Interestingly, Jozefowski and co-workers dem-
onstrated up-regulation of MARCO expression in J774 cells
in the presence of IL-12.35 However, our data indicate
that after 24 h of Mp infection, IL-12 p70 levels were not
different between THP-1 cell-derived macrophages with
and without a 6 h CSE pre-treatment. Therefore,
Figure 5 Co-localization of MARCO with Mycoplasma pneumoniae (Mp) on THP-1 cell-derived macrophages. Cells on 8-well cham-
ber slides were incubated with yellow fluorescent protein (YFP)-tagged Mp (1 CFU/cell) for 2 h, and then fixed in methanol for
double immunofluorescent staining of MARCO and YFP by using a monoclonal anti-MARCO antibody and a rabbit polyclonal anti-
YFP, followed by FITC-conjugated anti-mouse IgG and Texas Red-conjugated anti-rabbit IgG. (A) Mp (green color) on the surface
of THP-1 cell-derived macrophages. Blue color (DAPI staining) indicates cell nucleus. (B) MARCO staining on the same cell as shown
in (A); (C) overlay of (A) and (B) demonstrating co-localization of Mp and MARCO. (D) cells incubated with mouse and rabbit control
IgG (no MARCO and YFP antibody incubation) did not show any immunofluorescent staining. Original magnifications, x400.
Cigarette smoke and mycoplasma clearance 1609mechanisms responsible for CSE-induced reduction of
MARCO remain to be determined in our future experiments.
Since Mp can be detected in COPD patients,2,3 we exam-
ined the impact of CS on Mp clearance. We found that CS
decreased Mp clearance. Our findings have extended those
from Green and colleagues in that CSE caused a dose-
dependent inhibition of bacterial clearance by alveolar
macrophages.36 Here, we found that CSE reduced MARCO
expression and then impaired Mp clearance. Together, our
results have provided a novel pathway to explain an
increased bacterial burden in lungs of smokers. That is,
cigarette smoke reduces macrophage levels of receptors
(e.g., MARCO) that are required in host innate immune
responses to the invading bacteria, leading to dampened
bacterial clearance. We are aware that our research find-
ings in THP-1 cell-derived macrophages may not apply to
all types of macrophages. To further support the relevance
of our research findings in THP-1 cell-derived macrophages
to human alveolar macrophages, we recently collected
alveolar macrophages from bronchoalveolar lavage (BAL)
cells of two normal healthy human subjects. Alveolar
macrophages were obtained by adhering the BAL cells to
12-well tissue culture plates for 1 h at 37 C. After removing
the non-adherent BAL cells, adherent alveolar macrophages
were collected to measure MARCO mRNA levels (baseline).
The remainder of cells was exposed to 20% CSE for 6 h as
described for THP-1 cell-derived macrophages. Our prelim-
inary results suggest that like THP-1 cell-derived macro-
phages, human alveolar macrophages demonstrated
reduced (about 1.7-fold reduction) MARCO mRNA expres-
sion after 6 h of exposure to 20% CSE. In our future studies,
we will recruit more human subjects to obtain alveolarmacrophages from non-smokers as well as smokers with or
without COPD to evaluate MARCO expression levels, and
to further define a role of MARCO in bacterial clearance
in cigarette smoke-exposed alveolar macrophages.
Our study is an important step towards a better
understanding of MARCO’s role in bacterial infections in
the context of cigarette smoke exposure. Our findings will
be beneficial to future studies aimed at unraveling a role of
lung macrophages in host defense against bacterial
infections in individuals who smoke.
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